SIR-Spheres® Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says

- Health
  0

LONDON, March 31, 2016 /CNW/ – Sirtex (ASX: SRX) announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB)[1] stating that NHS doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as…